

## Illinois Medicaid COVID-19 Fee Schedule

**PLEASE NOTE:** New COVID-19 related codes will be added to the HFS system as they are released by the Centers for Medicare and Medicaid Services (CMS) in accordance with the [December 8, 2020 provider notice](#). Claims containing new codes which do not have a Medicare or National Government Services (NGS) rate will temporarily suspend until a code rate is assigned. Once a rate is assigned, the HFS system will be updated with that rate and any held claims released into processing.

### COVID-19 Vaccines and Vaccine Administration

COVID-19 vaccine product procedure codes are included as a reference but should not be billed when obtained at zero cost to the provider. COVID-19 vaccine administration procedure codes are billable by Physicians, Advance Practice Nurses (APNs), Physician Assistants (PAs), Local Health Departments, Federally Qualified Health Centers (FQHCs), Rural Health Clinics (RHCs), Encounter Rate Clinics (ERCs), and School-Based Health Centers (SBHCs).

**Please Note:** FQHCs, RHCs and ERCs must submit COVID-19 vaccine administration codes fee-for-service separately from an encounter claim, even if the vaccine was administered during a face-to-face encounter with a practitioner.

Procedure Code	Effective Date	Description	State Max Amount
91300	12/11/2020	Pfizer-BioNTech Covid-19 Vaccine (Aged 12 years and older) (Purple Cap)	N/A (currently government supplied at no cost to the provider)
0001A	12/11/2020 – 3/14/2021	Pfizer-BioNTech Covid-19 Vaccine (Purple Cap) Administration – First Dose	16.94
0001A	3/15/2021	Pfizer-BioNTech Covid-19 Vaccine (Purple Cap) Administration – First Dose	42.14
0002A	12/11/2020 – 3/14/2021	Pfizer-BioNTech Covid-19 Vaccine (Purple Cap) Administration – Second Dose	28.39
0002A	3/15/2021	Pfizer-BioNTech Covid-19 Vaccine (Purple Cap) Administration – Second Dose	42.14
0003A	8/12/2021	Pfizer-BioNTech Covid-19 Vaccine (Purple Cap) Administration – Third Dose	42.14
0004A	9/22/2021	Pfizer-BioNTech Covid-19 Vaccine (Purple Cap) Administration – Booster	42.14
91301	12/18/2020	Moderna Covid-19 Vaccine (Aged 12 years and older) (Red Cap)	N/A (currently government supplied at no cost to the provider)

0011A	12/18/2020 – 3/14/2021	Moderna Covid-19 Vaccine (Red Cap) Administration – First Dose	16.94
0011A	3/15/2021	Moderna Covid-19 Vaccine (Red Cap) Administration – First Dose	42.14
0012A	12/18/2020 – 3/14/2021	Moderna Covid-19 Vaccine (Red Cap) Administration – Second Dose	28.39
0012A	3/15/2021	Moderna Covid-19 Vaccine (Red Cap) Administration – Second Dose	42.14
0013A	8/12/2021	Moderna Covid-19 Vaccine (Red Cap) Administration – Third Dose	42.14
91303	2/27/2021	Janssen Covid-19 Vaccine (Aged 18 years and older)	N/A (currently government supplied at no cost to the provider)
0031A	2/27/2021 – 3/14/2021	Janssen (Johnson & Johnson) COVID-19 Vaccine Administration – Single Dose	28.39
0031A	3/15/2021	Janssen (Johnson & Johnson) COVID-19 Vaccine Administration – Single Dose	42.14
0034A	10/20/2021	Janssen (Johnson & Johnson) COVID-19 Vaccine Administration - Booster	42.14
91305	1/3/2022	Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Aged 12 years and older) (Gray Cap)	N/A (currently government supplied at no cost to the provider)
0051A	1/3/2022	Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - First dose	41.80
0052A	1/3/2022	Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - Second dose	41.80
0053A	1/3/2022	Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - Third dose	41.80
0054A	1/3/2022	Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - Booster	41.80

91306	10/20/2021	Moderna Covid-19 Vaccine (Aged 18 years and older) (Red Cap) (Low Dose)	N/A (currently government supplied at no cost to the provider)
0064A	10/20/2021	Moderna Covid-19 Vaccine (Red Cap) (Low Dose) Administration - Booster	42.14
91307	10/29/2021	Pfizer-BioNTech Covid-19 Pediatric Vaccine (Aged 5 years through 11 years) (Orange Cap)	N/A (currently government supplied at no cost to the provider)
0071A	10/29/2021	Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - First dose	42.14
0072A	10/29/2021	Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Second dose	42.14
0073A	01/03/2022	Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Third dose	41.80
0074A	05/17/2022	Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Booster	41.80
91308	06/17/2022	Pfizer-BioNTech Covid-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap)	N/A (currently government supplied at no cost to the provider)
0081A	06/17/2022	Pfizer-BioNTech COVID-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap) - Administration - First dose	41.80
0082A	06/17/2022	Pfizer-BioNTech COVID-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap) - Administration - Second dose	41.80
0083A	06/17/2022	Pfizer-BioNTech COVID-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap) - Administration - Third dose	41.80
91309	3/29/2022	Moderna Covid-19 Vaccine (Aged 6 years through 11 years or aged 18 years and older) (Blue Cap with purple border) 50MCG/0.5ML	N/A (currently government supplied at no cost to the provider)
0091A	6/17/2022	Moderna Covid-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) - Administration - First dose	41.80

0092A	6/17/2022	Moderna Covid-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) - Administration - Second dose	41.80
0093A	6/17/2022	Moderna Covid-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) - Administration - Third dose	41.80
0094A	3/29/2022	Moderna Covid-19 Vaccine (Aged 18 years and older)(Blue Cap with purple border) 50MCG/0.5ML Administration - Booster	41.80
91311	6/17/2022	Moderna Covid-19 Pediatric Vaccine (Aged 6 months through 5 years)(Blue Cap with magenta border) 250MCG/0.25ML	N/A (currently government supplied at no cost to the provider)
0111A	6/17/2022	Moderna Covid-19 Pediatric Vaccine (Aged 6 months through 5 years)(Blue Cap with magenta border) - Administration - First dose	41.80
0112A	6/17/2022	Moderna Covid-19 Pediatric Vaccine (Aged 6 months through 5 years)(Blue Cap with magenta border) - Administration - Second dose	41.80
0113A	6/17/2022	Moderna Covid-19 Pediatric Vaccine (Aged 6 months through 5 years)(Blue Cap with magenta border) - Administration - Third dose	41.80
M0201	6/8/2021	COVID-19 Vaccine Administration Inside a Patient's Home <b>Note:</b> please see the HFS <a href="#">7/2/21 provider notice</a> for information ; however, per <a href="#">CMS</a> billing of this code is no longer limited to once per DOS, per home effective 8/24/21	37.05

## **Vaccine Counseling**

**Billable by Local Health Departments, Physicians, Advance Practice Nurses (APNs), Physician Assistants (PAs), and School-Based Health Centers (SBHCs). Intended to provide reimbursement for the additional time needed for parental/caregiver counseling and informed consent for the COVID-19 vaccination of children ages 6 months through 20. \*Note: this code is *not billable as a telehealth service*.**

Procedure Code	Effective Date	Ages	Description	State Max Amount
99402	10/29/2021 for ages 5y-20y 6/17/2022 for ages 6mos-5y	6 months – 20 years	Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure) ; approximately 30 min.	30.00

### **Virtual Healthcare/Telehealth Expansion**

**Billable by Local Health Departments, Physicians, Advance Practice Nurses (APNs), and Physician Assistants (PAs) – including physicians, APNs, and PAs rendering the service in a Federally Qualified Health Center (FQHC), Rural Health Clinic (RHC), Encounter Rate Clinic (ERC), or School Based Health Center (SBHC):**

*\* Note: all virtual healthcare/telehealth codes must be billed with place of service 02 and GT modifier*

Procedure Code	Effective Date	Description	State Max Amount
G0406	3/9/2020	Follow-up inpatient consultation, limited, physicians typically spend 15 minutes communicating with the patient via telehealth	39.17
G0407	3/9/2020	Follow-up inpatient consultation, intermediate, physicians typically spend 25 minutes communicating with the patient via telehealth	72.13
G0408	3/9/2020	Follow-up inpatient consultation, complex, physicians typically spend 35 minutes communicating with the patient via telehealth	103.70
G0425	3/9/2020	Telehealth consultation, emergency department or initial inpatient, typically 30 minutes communicating with the patient via telehealth	100.35
G0426	3/9/2020	Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth	136.14
G0427	3/9/2020	Telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth	201.99
G2010	3/9/2020	Remote evaluation of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment	9.24
G2012	3/9/2020	Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care	13.19

		professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion	
G2061	3/9/2020 – 12/31/2020	Qualified nonphysician healthcare professional online assessment, for an established patient, for up to seven days, cumulative time during the 7 days; 5-10 minutes	12.10
G2062	3/9/2020 – 12/31/2020	Qualified nonphysician healthcare professional online assessment service, for an established patient, for up to seven days, cumulative time during the 7 days; 11-20 minutes	21.37
G2063	3/9/2020 – 12/31/2020	Qualified nonphysician qualified healthcare professional assessment service, for an established patient, for up to seven days, cumulative time during the 7 days; 21 or more minutes	33.14
G2250	1/1/2021	Remote assessment of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment	9.24
G2251	1/1/2021	Brief communication technology-based service, e.g. virtual check-in, by a qualified health care professional who cannot report evaluation and management services, provided to an established patient, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of clinical discussion	13.05
G2252	1/1/2021	Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion	25.14
98970	1/1/2021	Qualified nonphysician health care professional online digital assessment and management, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 min.	11.36
98971	1/1/2021	Qualified nonphysician health care professional online digital assessment and management, for an established patient, for up to 7 days, cumulative time during the 7 days; 11-20 min.	20.31
98972	1/1/2021	Qualified nonphysician health care professional online digital assessment and management, for an established patient, for up to 7 days, cumulative time during the 7 days; 21+ min.	32.41

99421	3/9/2020	Online Digital Evaluation and Management Service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes	13.19
99422	3/9/2020	Online Digital Evaluation and Management Service, for an established patient, for up to 7 days, cumulative time during the 7 days; 11-20 minutes	27.14
99423	3/9/2020	Online Digital Evaluation and Management Service, for an established patient, for up to 7 days, cumulative time during the 7 days; 21 or more minutes	43.23

**Please Note:** Evaluation and management services rendered by Physicians, Advance Practice Nurses, and Physician Assistants to new or existing patients using audio only telephonic equipment may be billed as a distant site telehealth service so long as the E/M service is of an amount and nature that would be sufficient to meet the key components of a face-to-face encounter. In this scenario, the claim must be submitted with Place of Service (POS) 02 and modifier GT appended to the applicable procedure code.

If an audio only telephonic interaction cannot meet key components of a face-to-face encounter, the provider may instead seek reimbursement for virtual check-in services using CPT code G2012. FQHCs/RHCs/ERCs will be reimbursed at the above rates (not their medical encounter rate) for virtual check-in and E-visit codes. Virtual check-in and e-visit/online portal services must be submitted fee-for-service without the T1015 encounter code.

## **Virtual Healthcare/Teledentistry Expansion**

### **Billable by Dentists:**

<b>Procedure Code</b>	<b>Effective Date</b>	<b>Description</b>	<b>State Max Amount</b>
D9995	3/9/2020	Teledentistry, synchronous; real-time encounter	13.19
D9996	3/9/2020	Teledentistry asynchronous; information stored and forwarded to dentist for subsequent review	9.24

**Note:** The above codes must be billed in addition to D0140, with place of service 02. Do not include the GT modifier.

## **COVID-19 Antibody Treatment and Administration**

COVID-19 antibody product procedure codes are included as a reference but should not be billed when obtained at zero cost to the provider. Only Q0247 was previously practitioner-purchased until it became unauthorized effective April 5, 2022.

Antibody treatment administration codes are billable by Physicians, Advance Practice Nurses (APNs), and Physician Assistants (PAs). Federally Qualified Health Centers (FQHCs), Rural Health Clinics

(RHCs), and Encounter Rate Clinics (ERCs) may bill antibody treatment administration codes as detail codes with an encounter claim.

**\*\*Hospitals may bill the antibody treatment administration codes marked with a double asterisk (\*\*)** using revenue code 0771. Reimbursement is based on DRG (inpatient setting) or EAPG (outpatient setting) methodology.

Procedure Code	Effective Date	Description & Labeler Name	State Max Amount
Q0220	12/8/2021	Tixagev and Cilgav, 300mg	N/A (currently government supplied at no cost to the provider)
M0220	12/8/2021	Injection, Tixagevimab and Cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	150.50
Q0221	2/24/2022	Injection, Tixagevimab and Cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg	N/A (currently government supplied at no cost to the provider)
M0221**	12/8/2021	Injection, Tixagevimab and Cilgavimab, for the pre-exposure prophylaxis only, for certain adults	** Billable only by hospitals on the 837I. Reimbursed using EAPG methodology.



		and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	
Q0222	2/11/2022	Injection, Bebtelovimab, 175 mg	N/A (currently government supplied at no cost to the provider)
M0222	2/11/2022	Intravenous injection, Bebtelovimab, includes injection and post administration monitoring	350.50
M0223**	2/11/2022	Intravenous injection, Bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	** Billable only by hospitals on the 837I. Reimbursed using EAPG methodology.
Q0243	11/21/2020 – 1/23/2022	Casirivimab and Imdevimab, 2400 mg (Regeneron)	N/A (currently government supplied at no cost to the provider)
M0243**	5/6/2021 – 1/23/2022	Intravenous infusion, Casirivimab and Imdevimab, includes infusion and post administration monitoring (Regeneron)	450.00 ** Hospitals billing on the 837I will be reimbursed using EAPG methodology.
M0244**	5/6/2021 – 1/23/2022	Intravenous infusion or subcutaneous injection, Casirivimab and Imdevimab includes infusion or injection, and post administration monitoring in the home or	** Billable only by hospitals on the 837I. Reimbursed using EAPG methodology.

		residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	
Q0245	2/9/2021 – 1/23/2022	Injection, Bamlanivimab and Etesevimab, 2100 mg (Eli Lilly)	N/A (currently government supplied at no cost to the provider)
M0245	5/6/2021 – 1/23/2022	Intravenous infusion, Bamlanivimab and Etesevimab, includes infusion and post administration monitoring (Eli Lilly)	450.00
M0246**	5/6/2021 – 1/23/2022	Intravenous infusion, Bamlanivimab and Etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	** Billable only by hospitals on the 837I. Reimbursed using EAPG methodology.
Q0247	10/1/2021 – 4/4/2022	Injection, Sotrovimab, 500 mg	2394.00
M0247	7/1/2021 – 4/4/2022	Intravenous infusion, Sotrovimab, includes infusion and post administration monitoring	450.00
M0248**	5/26/2021 – 4/4/2022	Intravenous infusion, Sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	** Billable only by hospitals on the 837I. Reimbursed using EAPG methodology.
Q0249	6/24/2021	Injection, Tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	N/A (currently government supplied at no cost to the provider)
M0249**	6/24/2021	Intravenous infusion, Tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving	** Billable only by hospitals on the 837I. Reimbursed using DRG methodology.

		systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	
M0250**	6/24/2021	Intravenous infusion, Tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	** Billable only by hospitals on the 837I. Reimbursed using DRG methodology.

## **Laboratory Services**

**Billable by Local Health Departments, Physicians, Advance Practice Nurses (APNs), Physician Assistants (PAs), and Independent Laboratories. Federally Qualified Health Centers (FQHCs), Rural Health Clinics (RHCs), and Encounter Rate Clinics (ERCs) may bill the following laboratory services as detail codes with an encounter claim when the laboratory service is performed on-site. Please note that providers normally subject to a SMART Act rate reduction (e.g. Independent Labs) must include modifier CR to exempt the COVID-related service from the rate reduction when billing outside HFS' COVID portal. It is not necessary to include the modifier when billing through the portal.**

**These rates also apply to hospitals who choose to have the Department generate their claim(s) within the HFS COVID Portal per the [February 8, 2021 provider notice](#) for uninsured individuals. For Medicaid-eligible participants, hospitals must bill on an institutional invoice and will be reimbursed via the EAPG methodology.**

<b>Procedure Code</b>	<b>Effective Date</b>	<b>Description</b>	<b>State Max Amount</b>
0202U	5/20/2020	Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	250.07
0223U	6/25/2020	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR,	416.78

		nasopharyngeal swab, each pathogen reported as detected or not detected	
0224U	6/25/2020	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed	42.13
0225U	8/10/2020	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected	416.78
0226U	8/10/2020	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum	42.28
0240U	10/6/2020	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	142.63
0241U	10/6/2020	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	142.63
86318	4/10/2020	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g. reagent strip)	16.90
86328	4/10/2020	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single-step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	45.23
86408	8/10/2020	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen	42.13
86409	8/10/2020	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer	105.33
86413	9/8/2020	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative	51.43
86769	4/10/2020	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	42.13
87426	6/25/2020	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric	35.33

		assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])	
87428	11/10/2020	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B SD: SARSCOV & INFVIRA&B AG IA	63.59
87635	3/13/2020	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	51.31
87636	10/6/2020	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	142.63
87637	10/6/2020	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	142.63
87811	10/6/2020	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	41.38
U0001	2/4/2020	CDC 2019-Novel Coronavirus real-time RT-PCR diagnostic panel	35.91
U0002	2/4/2020	Coronavirus (COVID-19) SARS-COV-2/2019-NCOV, Non-CDC Lab Test	51.31
U0003	4/14/2020 through 2/28/2021	Infectious Agent Detection by Nucleic Acid (DNA or RNA); SARS-COV-2, COVID-19, Amplified Probe Technique, High Throughput Technologies	100.00
U0003	3/1/2021	Infectious Agent Detection by Nucleic Acid (DNA or RNA); SARS-COV-2, COVID-19, Amplified Probe Technique, High Throughput Technologies	75.00
U0004	4/14/2020 through 2/28/2021	2019-NCOV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), Any Technique, Multiple Subtypes, Non-CDC, High Throughput Technologies	100.00
U0004	3/1/2021	2019-NCOV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), specimen collection. (*add-on to U0003 or U0004 Any Technique, Multiple Subtypes, Non-CDC, High Throughput Technologies	75.00

+U0005	3/1/2021	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date and time of; List separately in addition to either HCPCS code U0003 or U0004) <b><i>NOTE: certain conditions must be met to bill this code ; refer to the <a href="#">02/26/2021 provider notice</a> for billing guidelines</i></b>	25.00
--------	----------	--	-------

### **COVID-19 Diagnostic Testing Specimen Collection**

**\*Billable by Local Health Departments, Physicians, Advance Practice Nurses (APNs), Physician Assistants (PAs), and Federally Qualified Health Centers (FQHCs) with drive-thru testing sites. FQHCs may bill fee-for-service when there is not a billable medical encounter. Please note that providers normally subject to a SMART Act rate reduction (e.g. Independent Labs) must include modifier CR to exempt the COVID-related service from the rate reduction when billing outside HFS' COVID portal. It is not necessary to include the modifier when billing through the portal.**

**\*\*Billable by Local Health Departments, Physicians, Advance Practice Nurses (APNs), Physician Assistants (PAs), and Independent Labs.**

**\*\*\*Billable by Independent Labs only.**

<b>Procedure Code</b>	<b>Effective Date</b>	<b>Description</b>	<b>State Max Amount</b>
99000*	3/18/2020	Handling of Specimen for Transfer from Office to a Lab	23.46
G2023**	3/1/2020	Specimen Collection, SARS-CoV-2, COVID-19, any specimen source	23.46
G2024***	3/1/2020	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, any specimen source	25.46

## **COVID-19 Testing and Testing-Related Services for the Uninsured Population**

The following procedure codes are covered for the uninsured population for the purposes of COVID-19 testing and testing-related services for dates of service beginning March 18, 2020. Testing-related services include those directly related to the administration of an in vitro diagnostic product described in section 1905(a)(3)(B) of the Social Security Act, or to the evaluation of a patient for purposes of determining the need for such product.

HCPCS codes: G2010, G2012, G2023, G2024, G2061, G2062, G2063, G2250, G2251, G2252, T1015, U0001, U0002, U0003, U0004, U0005

CPT codes: All COVID-19 vaccine administration codes\*, 0224U, 0226U, 0240U, 0241U, 71045, 71046, 71047, 71048, 86318, 86328, 86408, 86409, 86413, 86769, 87426, 87428, 87635, 87636, 87637, 87811, 99000, 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99421, 99422, 99423

\*Note: All COVID-19 vaccine administration codes are billable for the uninsured population, effective with the specific code effective date.

Rates for these codes may be found on the COVID-19 Fee Schedule above, on the [Practitioner Fee Schedule](#) or, in the case of T1015, will be at the FQHC/RHC/ERC provider-specific medical encounter rate. Please note, effective dates for codes found on the COVID-19 fee schedule above are applicable, and CPT 99201 is an obsolete code effective with dates of service beginning 1/1/2021. Providers normally subject to a SMART Act rate reduction must include modifier CR to exempt the COVID-related service from the rate reduction when billing outside HFS' COVID portal. It is not necessary to include the modifier when billing through the portal.

As a reminder, Federally Qualified Health Centers (FQHCs) may bill specimen collection procedure code 99000 – Handling of Specimen for Transfer from Office to Lab, as fee-for-service utilizing the full functionality of the COVID portal. However, if an FQHC needs to bill a T1015 encounter for a testing-related service, it can only use the portal to obtain a RIN. The FQHC will have to submit the encounter claim through its normal billing process outside the portal once a RIN is obtained.